| Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy (NCT05667857) | Universitair Ziekenhuis Brussel | 2022-07-13 |
| Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy (NCT05817201) | Taizhou Hospital | 2022-07-01 |
| Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass (NCT05487469) | Nanjing Medical University | 2022-07-01 |
| Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy (NCT06202781) | Chinese PLA General Hospital | 2022-07-01 |
| Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric (NCT05387681) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2022-05-30 |
| TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer (NCT05314101) | Fujian Cancer Hospital | 2022-04-01 |
| SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma (NCT05218148) | Aiping Zhou | 2022-04-01 |
| PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer (NCT05311566) | Lei Li | 2022-03-27 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer (NCT05310383) | Lei Li | 2022-03-27 |
| Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium (NCT05273827) | Tianjin Medical University Cancer Institute and Hospital | 2022-03-22 |
| Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy (NCT05273255) | Michael Scharl | 2022-03-14 |
| A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer (NCT05216237) | Jiuda Zhao | 2022-02-15 |
| Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study (NCT05719324) | The First Affiliated Hospital with Nanjing Medical University | 2022-02-08 |
| Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer (NCT06391190) | RenJi Hospital | 2022-01-01 |
| the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer (NCT06378840) | RenJi Hospital | 2022-01-01 |
| Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation (NCT05460195) | Shanghai Chest Hospital | 2022-01-01 |
| Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) (NCT05136768) | Jun-Lin Yi, MD | 2021-12-01 |
| Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy (NCT04848454) | Peking University First Hospital | 2021-11-20 |
| Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. (NCT05176002) | Fujian Medical University Union Hospital | 2021-11-10 |
| Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer (NCT05223088) | Fujian Cancer Hospital | 2021-10-31 |
| Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer. (NCT05025514) | Centre Hospitalier Universitaire de Nīmes | 2021-10-19 |
| Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma (NCT04969354) | The Affiliated Hospital of Xuzhou Medical University | 2021-10-01 |
| Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC (NCT06818097) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-10-01 |
| Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer (NCT05161572) | Fudan University | 2021-09-28 |
| Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma (NCT05375734) | Second Affiliated Hospital of Nanchang University | 2021-08-17 |
| Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma (NCT05024266) | First Affiliated Hospital of Zhejiang University | 2021-08-01 |
| Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy (NCT05034289) | Rutgers, The State University of New Jersey | 2021-07-12 |
| Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy (NCT04037462) | VA Office of Research and Development | 2021-07-07 |
| Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment (NCT05813418) | Centre Hospitalier Universitaire, Amiens | 2021-07-02 |
| Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma (NCT04387500) | West China Hospital | 2021-07-01 |
| An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC (NCT04890522) | Sun Yat-sen University | 2021-07-01 |
| Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome (NCT04999943) | Affiliated Hospital to Academy of Military Medical Sciences | 2021-07-01 |
| The Effect of Education and Telephone Follow-up Given to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-care Power (NCT05683652) | Ankara Medipol University | 2021-06-30 |
| Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy (NCT04957511) | Viome | 2021-06-29 |
| Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment (NCT04706598) | Fudan University | 2021-06-09 |
| Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations (NCT04969029) | Tianjin Medical University Cancer Institute and Hospital | 2021-06-01 |
| Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. (NCT04720339) | University Hospital, Strasbourg, France | 2021-05-27 |
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML (NCT04722952) | The First Affiliated Hospital of Soochow University | 2021-05-01 |
| mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (NCT04895137) | Sixth Affiliated Hospital, Sun Yat-sen University | 2021-05-01 |
| Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma (NCT04521153) | Shanghai Zhongshan Hospital | 2021-03-25 |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer (NCT04670445) | Massachusetts General Hospital | 2021-01-23 |
| Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma (NCT05476965) | Hubei Cancer Hospital | 2021-01-01 |
| Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection (NCT04682210) | Sun Yat-sen University | 2020-12-01 |
| Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer (NCT04539600) | Sun Yat-sen University | 2020-11-01 |
| Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease (NCT04805099) | Hellenic Cooperative Oncology Group | 2020-11-01 |
| Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors (NCT04587817) | Peking University First Hospital | 2020-10-15 |
| Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy (NCT04283539) | National Jewish Health | 2020-09-23 |
| MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study (NCT04500990) | Peking University | 2020-09-01 |
| Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC (NCT04372732) | Shanghai Pulmonary Hospital, Shanghai, China | 2020-09-01 |
| Immunological Response After Shrimp Oral Immunotherapy Treatment (NCT04552522) | Mahidol University | 2020-08-28 |
| Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC (NCT04547452) | West China Hospital | 2020-07-01 |
| Immunotherapy in Lung Cancer: Treatment After IO Cessation. (NCT04465942) | European Lung Cancer Working Party | 2020-06-26 |
| Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) (NCT04271813) | Shanghai Changzheng Hospital | 2020-06-01 |
| Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. (NCT04405622) | Sun Yat-sen University | 2020-05-30 |
| Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors (NCT04389684) | Poitiers University Hospital | 2020-05-27 |
| Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma (NCT04156698) | Eye & ENT Hospital of Fudan University | 2020-05-21 |
| Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure (NCT04586088) | Sun Yat-sen University | 2020-05-05 |
| Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients (NCT04441424) | Alkarkh Health Directorate-Baghdad | 2020-04-03 |
| The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients (NCT04397575) | Federation Francophone de Cancerologie Digestive | 2020-04-03 |
| Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy (NCT04641884) | Nantes University Hospital | 2020-04-01 |
| Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) (NCT04278222) | Shanghai Changzheng Hospital | 2020-02-10 |
| Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (NCT04169841) | Centre Georges Francois Leclerc | 2020-02-10 |
| A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC (NCT04807114) | Universitaire Ziekenhuizen KU Leuven | 2020-02-01 |
| A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade (NCT04807127) | Universitaire Ziekenhuizen KU Leuven | 2020-02-01 |
| Low-moderate Intensity Pedaling During Immunotherapy Administration (NCT04127318) | Rush University Medical Center | 2020-01-31 |
| Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas (NCT04570683) | Bispebjerg Hospital | 2020-01-27 |
| Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma (NCT04225364) | Guangzhou Institute of Respiratory Disease | 2020-01-17 |
| Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy (NCT04225390) | University of Erlangen-Nürnberg Medical School | 2020-01-13 |
| Camrelizumab Combined With Local Treatment in NSCLC Patients With BM (NCT04291092) | Zhejiang Cancer Hospital | 2020-01-01 |
| COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer (NCT03898895) | Sun Yat-sen University | 2019-12-10 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy (NCT04188860) | Lei Li | 2019-12-06 |
| Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer (NCT06849362) | Yue Gou | 2019-12-01 |
| Omalizumab to Accelerate a Symptom-driven Multi-food OIT (NCT04045301) | Philippe Bégin | 2019-11-11 |
| Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer (NCT04231552) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-11-10 |
| Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer (NCT04558684) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-11-01 |
| Cardiovascular Effects of CART Cell Therapy (NCT04026737) | Abramson Cancer Center at Penn Medicine | 2019-07-22 |
| AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies. (NCT04145232) | Ardigen | 2019-06-13 |
| PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer (NCT03971214) | Chinese Academy of Medical Sciences | 2019-06-01 |
| Evaluation of Pain Alleviating Strategies During Allergy Shots (NCT04181632) | Nemours Children's Clinic | 2019-05-20 |
| Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC (NCT05637580) | Guangdong Provincial People's Hospital | 2019-05-20 |
| The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China (NCT04286841) | Guangdong Association of Clinical Trials | 2019-05-01 |
| BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics (NCT04136470) | Ardigen | 2019-04-01 |
| Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer (NCT04110093) | Shanghai Changzheng Hospital | 2019-03-01 |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms (NCT06065592) | Lebanese University | 2019-02-01 |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy (NCT03589339) | Nanobiotix | 2019-01-16 |
| Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH) (NCT05321212) | University Hospital, Brest | 2019-01-02 |
| Study on the Applicability of CCR Criteria in Rectal Cancer (NCT06794099) | Peking University Cancer Hospital & Institute | 2019-01-01 |
| SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC (NCT06889649) | Peking University First Hospital | 2019-01-01 |
| An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal (NCT05225844) | Harbin Medical University | 2019-01-01 |
| Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC (NCT06461936) | Chen Xiaoping | 2019-01-01 |
| Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer (NCT03765190) | Peking University First Hospital | 2019-01-01 |
| Combination of Hypofractionated Proton Therapy With Immunotherapy (NCT03764787) | Peking University First Hospital | 2019-01-01 |
| Changes in the Microenvironment of HPV-induced Head and Neck Cancers in West Indies and Metropolitan Population (NCT03580070) | University Hospital Center of Martinique | 2018-12-07 |
| Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies (NCT03722186) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-13 |
| Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG (NCT03695757) | Ajou University School of Medicine | 2018-11-06 |
| PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities (NCT03693326) | Asan Medical Center | 2018-11-01 |
| Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy (NCT04993378) | Shen Lin | 2018-11-01 |
| Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy (NCT05334849) | Lin Chen | 2018-11-01 |
| Effect of Chemotherapy on PD-L1 in NSCLC (NCT03701607) | Baodong Qin | 2018-09-01 |
| Effect of Chemotherapy on TMB in NSCLC (NCT03683407) | Baodong Qin | 2018-09-01 |